Imfinzi Drug Interactions
Currently displaying 105 drugs known to have a moderate interaction with Imfinzi (durvalumab).
- 44 major drug interactions
- 105 moderate drug interactions
Moderate interactions with Imfinzi (durvalumab)
Note: Showing generic names only.
A
B
C
- canakinumab
- candida albicans extract
- cholera vaccine
- coccidioidin skin test
- cortisone
- COVID-19 mRNA (Moderna) vaccine
- COVID-19 mRNA (Pfizer) vaccine
D
E
H
- haemophilus b conjugate (hboc) vaccine
- haemophilus b conjugate (prp-omp) vaccine
- haemophilus b conjugate (prp-t) vaccine
- hepatitis a adult vaccine
- hepatitis a pediatric vaccine
- hepatitis b adult vaccine
- hepatitis b pediatric vaccine
- histoplasmin
- human papillomavirus vaccine
- hydrocortisone
I
- idelalisib
- influenza virus vaccine, h1n1, inactivated
- influenza virus vaccine, h5n1
- influenza virus vaccine, inactivated
J
L
- lactobacillus acidophilus
- lactobacillus reuteri
- lactobacillus rhamnosus
- lactobacillus rhamnosus gg
- lyme disease vaccine
M
- meningococcal conjugate vaccine
- meningococcal group acwy conjugate-group b vaccine (cvx 316)
- meningococcal group B vaccine
- meningococcal polysaccharide vaccine
- methylprednisolone
- mixed respiratory vaccine
- monomethyl fumarate
- mumps skin test antigen
O
P
- pertussis, acellular
- plague vaccine
- pneumococcal 13-valent vaccine
- pneumococcal 15-valent conjugate vaccine
- pneumococcal 20-valent conjugate vaccine
- pneumococcal 21-valent conjugate vaccine
- pneumococcal 23-polyvalent vaccine
- pneumococcal 7-valent vaccine
- poliovirus vaccine, inactivated
- prednisolone
- prednisone
R
- rabies vaccine, human diploid cell
- rabies vaccine, purified chick embryo cell
- rilonacept
- roflumilast
- rozanolixizumab
- rsv vaccine pref3, recombinant
- rsv vaccine, mrna
- rsv vaccine, pref a-pref b, recombinant
S
- saccharomyces boulardii lyo
- sars-cov-2 (covid-19) ad26 vaccine, recombinant
- sars-cov-2 (covid-19) chadox1 vaccine, recombinant
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 310)
- sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant
- sars-cov-2 (covid-19) rs-nanoparticle vaccine, recombinant
- sars-cov-2 mrna (tozinameran 5y-11y) vaccine
- sars-cov-2 mrna (tozinameran 6m-4y) vaccine
- sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine
- sars-cov-2 mrna (tozinameran) vaccine
- sars-cov-2 mrna-1273 (6m-5y) vaccine
- sars-cov-2 mrna-1273 (6y-11y) vaccine
- sars-cov-2 mrna-1273 (booster only) vaccine
- sars-cov-2 nvx-cov2373 vaccine, recomb (cvx 313)
- sars-cov-2 pres dtm (booster only) vaccine, recombinant
- sipuleucel-T
- skin test antigens, multiple
- smallpox and mpox vaccine
- staphage lysate (spl)
- streptococcus salivarius
T
- tetanus toxoid
- tick-borne encephalitis (inactivated) pediatric vaccine
- tick-borne encephalitis (inactivated) vaccine
- triamcinolone
- trichophyton skin test
- tuberculin purified protein derivative
- typhoid vaccine, inactivated
U
Z
Imfinzi disease interactions
There are 11 disease interactions with Imfinzi (durvalumab) which include:
- adrenal insufficiency
- colitis
- diabetes
- infections
- liver dysfunction
- renal dysfunction
- thyroid disorders
- Durvalumab – pneumonitis
- HSCT
- myasthenia gravis
- organ transplant
More about Imfinzi (durvalumab)
- Imfinzi consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.